Westover Capital Advisors LLC Makes New $1.11 Million Investment in Krystal Biotech, Inc. $KRYS

Westover Capital Advisors LLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,332 shares of the company’s stock, valued at approximately $1,108,000.

Other large investors have also bought and sold shares of the company. Silvant Capital Management LLC bought a new stake in shares of Krystal Biotech in the 2nd quarter worth $30,000. Western Wealth Management LLC purchased a new stake in shares of Krystal Biotech in the first quarter valued at about $34,000. USA Financial Formulas bought a new position in shares of Krystal Biotech during the first quarter valued at about $44,000. Integrated Wealth Concepts LLC bought a new position in shares of Krystal Biotech during the second quarter valued at about $46,000. Finally, Signaturefd LLC lifted its position in shares of Krystal Biotech by 27.3% during the third quarter. Signaturefd LLC now owns 168 shares of the company’s stock valued at $56,000 after purchasing an additional 36 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $313.66 on Tuesday. Krystal Biotech, Inc. has a 1 year low of $183.26 and a 1 year high of $382.54. The firm has a market cap of $9.28 billion, a PE ratio of 39.31 and a beta of 0.50. The stock has a fifty day moving average price of $338.84 and a 200-day moving average price of $307.01.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 7.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on KRYS shares. HC Wainwright reaffirmed a “buy” rating and issued a $361.00 price objective on shares of Krystal Biotech in a research report on Thursday, October 15th. Weiss Ratings upgraded shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. Citigroup reissued a “buy” rating on shares of Krystal Biotech in a research report on Thursday, October 15th. Finally, The Goldman Sachs Group began coverage on Krystal Biotech in a research note on Thursday, September 24th. They issued a “buy” rating and a $441.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Krystal Biotech currently has an average rating of “Buy” and a consensus target price of $377.20.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares in the company, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 13.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.